On this page
Aspartylglucosaminuria
This condition results from a deficiency of the aspartylglucosaminidase enzyme, causing a build-up of specific waste products in lysosomes. It primarily affects the nervous system and connective tissues, leading to progressive intellectual disability and physical changes.
Available at Jeen Health
Clinical tests that include this
Overview
Aspartylglucosaminuria (AGU) is a lysosomal storage disorder, meaning it is part of a group of conditions where cells cannot properly recycle certain waste materials. Specifically, AGU results from a defect in the breakdown of glycoproteins, which are proteins with attached sugar chains important for many bodily functions [PMID:33678484]. Without the necessary enzyme, these complex molecules accumulate within the lysosomes - structures within cells responsible for waste processing - leading to cellular dysfunction and damage.
While AGU is considered a rare condition globally, it is more commonly observed in the Finnish population, where its prevalence is estimated to be approximately 1 in 18,000 live births. Elsewhere, the exact prevalence is not well established [PMID:20301389].
Symptoms & clinical features
The symptoms of aspartylglucosaminuria typically begin in early childhood, often presenting as developmental delays. Over time, these delays progress to intellectual disability, which can range from mild to severe. Speech development is often particularly affected.
Beyond neurological symptoms, individuals with AGU may also experience a range of physical features. These can include coarse facial features, joint hypermobility (joints that move beyond the normal range), and skeletal abnormalities. Behavioural challenges, such as hyperactivity, may also be observed. The condition is progressive, meaning symptoms tend to worsen over time, often leading to increasing dependency into adulthood.
Video: Genetics 101
Affected organs
Aspartylglucosaminuria primarily affects the brain and nervous system, leading to the characteristic intellectual disability and developmental regression. The accumulation of abnormal substances within neuronal cells disrupts their normal function, impacting cognitive abilities and motor skills.
Connective tissues throughout the body are also commonly affected. This can manifest as problems with bones and joints, contributing to some of the physical features seen in individuals with AGU. Other organ systems, such as the liver or spleen, may show milder involvement, but the most significant impact is on neurological function.
Risks & severity
AGU is a progressive disorder, meaning its symptoms gradually become more severe over time. Initial developmental delays in infancy typically advance to significant intellectual disability by school age and beyond [PMID:20301389]. The rate of progression and the specific severity of symptoms can vary among affected individuals, even within the same family.
Life expectancy in individuals with AGU is generally reduced compared to the general population, though specific figures can vary. The progressive neurological decline often leads to increasing care needs throughout life. There are currently no known factors that reliably predict the exact course or severity of the disease in an individual.
Genetic causes
Aspartylglucosaminuria is caused by pathogenic variants in the 'aspartylglucosaminidase' (AGA) gene. This gene provides instructions for making an enzyme also called aspartylglucosaminidase. This enzyme is crucial for the normal functioning of lysosomes, which are often referred to as the 'recycling centres' of the cell [PMID:33678484].
Within lysosomes, the AGA enzyme's job is to break a specific chemical bond in complex sugar-protein molecules known as glycoproteins. This process is one of the final steps in the complete degradation and recycling of these molecules. When pathogenic variants occur in the AGA gene, the enzyme either does not work correctly or is not produced at all. This leads to the build-up of partially broken down glycoproteins inside the lysosomes, causing them to swell and impair cellular function, particularly in the brain and connective tissues.
- AGA aspartylglucosaminidaseThe AGA gene provides instructions for producing aspartylglucosaminidase, an enzyme vital for the breakdown of certain complex sugar-protein molecules within cellular recycling centres called lysosomes.
Inheritance pattern
Aspartylglucosaminuria has an autosomal recessive inheritance pattern. This means that a person must inherit two altered copies of the AGA gene - one from each parent - to develop the condition.
Individuals who inherit only one altered copy of the AGA gene are known as carriers. Carriers typically do not show any symptoms of AGU because their one working copy of the gene is sufficient to produce enough functional enzyme. When two carriers have a child, there is a 25% chance with each pregnancy that the child will inherit two altered copies of the gene and develop AGU. There is a 50% chance the child will also be a carrier, and a 25% chance they will inherit two normal copies of the gene and not be affected or a carrier.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
A diagnosis of aspartylglucosaminuria is typically suspected based on a person's clinical symptoms, such as developmental delay, intellectual disability, and characteristic physical features. The suspicion can be confirmed through biochemical and genetic testing. Biochemical tests can detect the accumulation of specific waste products (oligosaccharides) in urine samples and measure the activity of the aspartylglucosaminidase enzyme in blood cells or skin samples. Reduced enzyme activity supports a diagnosis.
Definitive confirmation of AGU is achieved through genetic testing, which identifies pathogenic variants in the AGA gene. In the UK, genetic testing for suspected cases of lysosomal storage disorders like AGU would typically be accessed via the NHS Genomic Medicine Service (GMS). Referrals for genetic testing and counselling are usually made by a paediatrician, neurologist, or clinical geneticist following initial clinical assessment. AGU is covered by an NHS National Genomic Test Directory R-code, facilitating standardised testing pathways.
Management & lifestyle
Currently, there is no cure for aspartylglucosaminuria, and management focuses on providing supportive care to address the symptoms and improve quality of life. This involves a multidisciplinary team approach, often including paediatricians, neurologists, physiotherapists, occupational therapists, speech and language therapists, and educational specialists.
Physical therapy and occupational therapy can help address motor skill challenges and maintain joint mobility. Speech and language therapy supports communication development. Educational support is crucial for individuals with intellectual disabilities. In some regions, experimental treatments such as enzyme replacement therapy or gene therapy are being investigated, but these are not routinely available and their long-term efficacy for AGU is still under study. Genetic counselling is an important part of the management pathway, providing information about the condition, its inheritance, and reproductive options for families.
UK care pathway
In the UK, if aspartylglucosaminuria is suspected, a person would generally be referred to a clinical geneticist or specialist paediatrician within the NHS. These specialists can evaluate symptoms, arrange appropriate diagnostic tests, and coordinate care. Genetic testing is available through the NHS Genomic Medicine Service (GMS) as part of the National Genomic Test Directory, typically under a relevant R-code for lysosomal storage disorders. Access to genetic counselling is also an integral part of this pathway, offering families support and information about the genetic aspects of the condition and what it means for family planning.
Frequently asked questions
What is a lysosomal storage disorder?
Lysosomal storage disorders are a group of rare genetic conditions caused by specific enzyme deficiencies within lysosomes, which are like the 'recycling centres' of cells. When an enzyme is missing or doesn't work correctly, waste materials build up inside the lysosomes, leading to cellular damage and impacting various organs and bodily functions.
Can carriers of aspartylglucosaminuria have symptoms?
No, carriers of aspartylglucosaminuria typically do not experience any symptoms of the condition. They have one working copy of the AGA gene, which is usually sufficient to produce enough functional enzyme to prevent the build-up of waste products within their cells.
Is there a cure for aspartylglucosaminuria?
Currently, there is no cure for aspartylglucosaminuria. Treatment focuses on supportive care to manage symptoms, improve quality of life, and address specific challenges as they arise. Research into potential new therapies, such as gene therapy, is ongoing.
How is aspartylglucosaminuria inherited?
Aspartylglucosaminuria is inherited in an autosomal recessive pattern. This means that a child must inherit two altered copies of the AGA gene, one from each parent, to develop the condition. Parents who each carry one altered gene copy usually show no symptoms themselves but have a 25% chance of having an affected child with each pregnancy.
If someone in my family has AGU, should I be tested?
If someone in your family has been diagnosed with AGU, it can be helpful to speak with a genetic counsellor. They can assess your family history, explain the inheritance pattern, and discuss whether genetic testing for carrier status is appropriate for you and other family members.
References
- Adam MP, Bick S, Mirzaa GM. Aspartylglucosaminuria. 1993. PMID: 38252773
- Goodspeed K, Feng C, Laine M. Aspartylglucosaminuria: Clinical Presentation and Potential Therapies. Journal of child neurology. 2021. PMID: 33439067
- Arvio M, Mononen I. Aspartylglycosaminuria: a review. Orphanet journal of rare diseases. 2016. PMID: 27906067
- Tokola A, Laine M, Tikkanen R. Susceptibility-Weighted Imaging Findings in Aspartylglucosaminuria. AJNR. American journal of neuroradiology. 2019. PMID: 31649158
- Roine U, Tokola AM, Autti T. Topological Structural Brain Connectivity Alterations in Aspartylglucosaminuria: A Case-Control Study. AJNR. American journal of neuroradiology. 2023. PMID: 36549851
- Cantz M, Ulrich-Bott B. Disorders of glycoprotein degradation. Journal of inherited metabolic disease. 1990. PMID: 2122119
- Halila R, Ikonen E, Tollersrud O. Aspartylglucosaminuria (AGU): protein and gene structure of normal and mutated aspartylglucosaminidase. Biochemical medicine and metabolic biology. 1993. PMID: 8373629
- Arvio P, Arvio M. Progressive nature of aspartylglucosaminuria. Acta paediatrica (Oslo, Norway : 1992). 2002. PMID: 12022293